A Double Blind, Placebo Controlled Randomized Phase II Trial Of Gemcitabine And Cisplatin With Or Without The VEGF Inhibitor Bevacizumab (NSC #704865) In Patients With Malignant Mesotheloma
This randomized phase II trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have malignant mesothelioma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known if combination chemotherapy works better with or without bevacizumab in treating malignant mesothelioma.
NCT00027703 — Recurrent Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/recurrent-malignant-mesothelioma/NCT00027703/
Phase II Study Of ET-743 In Patients With Unresectable Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.
NCT00027508 — Malignant Mesothelioma
Status: Terminated
http://inclinicaltrials.com/malignant-mesothelioma/NCT00027508/
A Phase II Study Of ZD 1839 (NSC 715055, IND 61187) In Patients With Malignant Mesothelioma
Phase II trial to study the effectiveness of gefitinib in treating patients who have malignant mesothelioma. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of malignant mesothelioma
NCT00025207 — Recurrent Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/recurrent-malignant-mesothelioma/NCT00025207/
Phase I Study of Decitabine Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Lung Cancer Patients
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable lung or esophageal cancer or malignant mesothelioma of the pleura.
NCT00019825 — Lung Cancer
Status: Completed
http://inclinicaltrials.com/lung-cancer/NCT00019825/
Phase II Study of Gemcitabine and Epirubicin for the Treatment of Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have malignant mesothelioma.
NCT00017186 — Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/malignant-mesothelioma/NCT00017186/
A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if radiation therapy is effective in preventing metastatic cancer following surgery. PURPOSE: Randomized phase III trial to determine the effectiveness of radiation therapy in preventing metastatic cancer in patients who have undergone diagnostic procedures to identify malignant mesothelioma.
NCT00006231 — Perioperative/Postoperative Complications
Status: Completed
http://inclinicaltrials.com/perioperative-postoperative-complications/NCT00006231/
Treatment of Malignant Pleural Mesothelioma With Gene Modified Cancer Cell Lines
RATIONALE: Ganciclovir may ease some of the side effects of cancer treatment. Vaccines made from a person's modified malignant mesothelioma cells may make the cancer more sensitive to ganciclovir. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus ganciclovir in treating patients who have stage I, stage II, or stage III malignant mesothelioma.
NCT00006216 — Malignant Mesothelioma
Status: Active, not recruiting
http://inclinicaltrials.com/malignant-mesothelioma/NCT00006216/
A Phase II Trial of SU5416 (NSC# 696819) in Patients With Malignant Mesothelioma
Phase II trial to study the effectiveness of SU5416 in treating patients who have malignant mesothelioma. SU5416 may stop the growth of malignant mesothelioma by stopping blood flow to the tumor.
NCT00006014 — Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/malignant-mesothelioma/NCT00006014/
Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether receiving cisplatin with raltitrexed is more effective than cisplatin alone for malignant mesothelioma. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without raltitrexed in treating patients who have malignant mesothelioma of the pleura.
NCT00004920 — Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/malignant-mesothelioma/NCT00004920/
Phase II Study on Tomusex in Malignant Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of raltitrexed in treating patients who have malignant mesothelioma that cannot be surgically removed.
NCT00004254 — Malignant Mesothelioma
Status: Completed
http://inclinicaltrials.com/malignant-mesothelioma/NCT00004254/